Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Income from Continuing Operations for 7 consecutive years, with 23461000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 49.03% year-over-year to 23461000.0, compared with a TTM value of 87014000.0 through Dec 2025, up 146.44%, and an annual FY2025 reading of 87014000.0, up 146.44% over the prior year.
  • Income from Continuing Operations was 23461000.0 for Q4 2025 at Keros Therapeutics, down from 7280000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 148451000.0 in Q1 2025 and bottomed at 52956000.0 in Q3 2024.
  • Average Income from Continuing Operations over 5 years is 21685150.0, with a median of 28492000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 328.21% in 2022, then surged 444.32% in 2025.
  • Year by year, Income from Continuing Operations stood at 6940000.0 in 2021, then plummeted by 328.21% to 29718000.0 in 2022, then crashed by 56.32% to 46455000.0 in 2023, then grew by 0.92% to 46026000.0 in 2024, then surged by 49.03% to 23461000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for KROS at 23461000.0 in Q4 2025, 7280000.0 in Q3 2025, and 30696000.0 in Q2 2025.